1. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.
2. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics, 2011. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda; 2011. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/ . Accessed December 2013.
3. American Diabetes Association (ADA). The Cost of Diabetes, 2012. American Diabetes Association, Alexandria; 2013. http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html . Accessed December 2014.
4. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47. doi: 10.1016/S0140-6736(09)60659-0 .
5. DeVries JH, Bain SC, Rodbard HW, Seufert J, D’Alessio D, Thomsen AB, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35(7):1446–54. doi: 10.2337/dc11-1928 .